By: Shawn Arrajj
Adolescents and young adults with chronic migraines saw significant reductions in daily headaches and in headache disability scores after treatments of onabotulinumtoxin A, according to data published in Pediatric Neurology. The study is the first prospective study to show the efficacy of onabotulinumtoxin A (Botox, AbbVie) injections in reducing headache days in the pediatric population,












